Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (27559) 27559
Book / eBook (1385) 1385
Publication (1127) 1127
Book Review (483) 483
Newsletter (483) 483
Magazine Article (339) 339
Newspaper Article (262) 262
Book Chapter (181) 181
Trade Publication Article (51) 51
Conference Proceeding (39) 39
Government Document (15) 15
Dissertation (10) 10
Reference (4) 4
Data Set (3) 3
Transcript (2) 2
Web Resource (2) 2
Paper (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (23721) 23721
female (12543) 12543
male (12050) 12050
index medicus (8380) 8380
adult (8152) 8152
middle aged (7964) 7964
dermatology (7808) 7808
drug eruptions - etiology (5667) 5667
aged (5365) 5365
drug therapy (3618) 3618
treatment outcome (3327) 3327
adolescent (2662) 2662
child (2589) 2589
skin (2236) 2236
diagnosis, differential (2144) 2144
animals (2078) 2078
care and treatment (2035) 2035
therapy (1954) 1954
medicine & public health (1920) 1920
drugs (1830) 1830
pharmacology & pharmacy (1691) 1691
diagnosis (1671) 1671
skin - pathology (1663) 1663
allergy (1538) 1538
health aspects (1520) 1520
dermatology & venereal diseases (1494) 1494
risk factors (1464) 1464
drug therapy, combination (1457) 1457
child, preschool (1410) 1410
drug eruptions - pathology (1406) 1406
research (1400) 1400
chemotherapy (1352) 1352
aged, 80 and over (1342) 1342
immunology (1339) 1339
drug eruptions - diagnosis (1320) 1320
oncology (1312) 1312
medicine, general & internal (1290) 1290
antineoplastic agents - adverse effects (1277) 1277
complications and side effects (1253) 1253
follow-up studies (1236) 1236
cancer (1204) 1204
pediatrics (1192) 1192
biopsy (1090) 1090
infant (1088) 1088
pharmacology/toxicology (1076) 1076
skin diseases (1073) 1073
administration, topical (1063) 1063
retrospective studies (1063) 1063
young adult (1048) 1048
psoriasis (1031) 1031
administration, oral (974) 974
disease (973) 973
anti-bacterial agents - therapeutic use (972) 972
severity of illness index (970) 970
analysis (930) 930
children (888) 888
patients (885) 885
time factors (863) 863
dosage and administration (832) 832
psoriasis - drug therapy (827) 827
toxic epidermal necrolysis (825) 825
case studies (804) 804
internal medicine (801) 801
immunosuppressive agents - therapeutic use (797) 797
management (777) 777
dermatitis (774) 774
dose-response relationship, drug (773) 773
side effects (767) 767
pharmacology (757) 757
anti-inflammatory agents - therapeutic use (732) 732
antineoplastic agents - therapeutic use (727) 727
drug administration schedule (717) 717
medicine (705) 705
antiviral agents - therapeutic use (677) 677
drug hypersensitivity - etiology (669) 669
toxicology (668) 668
recurrence (660) 660
adrenal cortex hormones - therapeutic use (658) 658
double-blind (658) 658
pregnancy (656) 656
infectious diseases (655) 655
efficacy (652) 652
dermatologic agents - therapeutic use (646) 646
drug eruptions (645) 645
skin diseases - drug therapy (636) 636
case report (633) 633
drug safety and pharmacovigilance (632) 632
antibodies, monoclonal - adverse effects (631) 631
anti-bacterial agents - adverse effects (629) 629
risk assessment (628) 628
medical research (621) 621
skin - drug effects (614) 614
drug eruptions - drug therapy (612) 612
corticosteroids (608) 608
hypersensitivity (603) 603
rheumatology (593) 593
prognosis (587) 587
infection (586) 586
usage (583) 583
inflammation (571) 571
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (970) 970
UTL at Downsview - May be requested (94) 94
Robarts - Stacks (82) 82
UofT at Mississauga - Stacks (54) 54
Collection Dvlpm't (Acquisitions) - Closed Orders (51) 51
Collection Dvlpm't (Acquisitions) - Vendor file (30) 30
UofT at Scarborough - Stacks (25) 25
Dentistry (Harry R Abbott) - Stacks (21) 21
OISE - Stacks (17) 17
Providence Healthcare - Stacks (17) 17
Online Resources - Online (15) 15
Scarborough Hospital - General (15) 15
Dentistry (Harry R Abbott) - Withdrawn (14) 14
St. Michael's College (John M. Kelly) - 2nd Floor (14) 14
Gerstein Science - Reference (11) 11
Lakeridge Health Sciences - Oshawa (11) 11
Humber River Regional Hospital - Church Stacks (10) 10
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (8) 8
Earth Sciences (Noranda) - Stacks (8) 8
Gerstein Science - Missing (8) 8
Royal Ontario Museum - Stacks (7) 7
Toronto East General Hospital - Stacks (7) 7
Victoria University E.J. Pratt - Stacks (7) 7
Credit Valley Hospital - Stacks (6) 6
Gerstein Science - Circulation Desk (6) 6
Law (Bora Laskin) - Stacks (6) 6
Providence Healthcare - Reference (6) 6
Scarborough Hospital - Birchmount (6) 6
St. Michael's Hospital - Stacks (6) 6
Stacks (6) 6
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (6) 6
New College (Ivey) - Stacks (5) 5
Criminology - Stacks (4) 4
Humber River Regional Hospital - Finch Stacks (4) 4
Markham Stouffville Hospital - Stacks (4) 4
Scarborough Hospital - Hospital Department (4) 4
Thomas Fisher Rare Book - Rare Book (4) 4
Chemistry (A D Allen) - Stacks (3) 3
Holland Bloorview Kids Rehabilitation - Stacks (3) 3
St. Michael's College (John M. Kelly) - 3rd Floor (3) 3
University College (Laidlaw) - Stacks (3) 3
Earth Sciences (Noranda) - Reference (2) 2
Gerstein Science - Course Reserves (2) 2
Gerstein Science - Periodical Stacks (2) 2
Humber River Regional Hospital - Keele Stacks (2) 2
Pharmacy (2) 2
Pontifical Inst. Mediaeval Studies - Library use only (2) 2
Trinity College (John W Graham) - Stacks (2) 2
UofT at Mississauga - Reference (2) 2
Victoria University E.J. Pratt - Northrop Frye (2) 2
West Park Healthcare Centre - Hospital Department (2) 2
West Park Healthcare Centre - Stacks (2) 2
Women's College Hospital - Stacks (2) 2
Art - Library use only (1) 1
Baycrest Hospital - Course Reserves (1) 1
Baycrest Hospital - Stacks (1) 1
Credit Valley Hospital - Missing (1) 1
Credit Valley Hospital - Reference (1) 1
Credit Valley Hospital - Reserve desk (1) 1
Dentistry (Harry R Abbott) - Circulation Desk (1) 1
East Asian (Cheng Yu Tung) - Reference (1) 1
Faculty of Information - Subject Analysis Systems (1) 1
Gerstein Science - May be requested (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Gerstein Science - Oversize (1) 1
Gerstein Science - Pharmacy (1) 1
Gerstein Science - Searching (1) 1
Humber River Regional Hospital - Pharmacy (1) 1
Indust. Rel's & Hum. Resources (Newman) - Library use only (1) 1
May be requested (1) 1
Mt Sinai Hospital - Pathology (1) 1
Mt Sinai Hospital - Stacks (1) 1
New College (Ivey) - Withdrawn (1) 1
OISE - Lost (1) 1
Online (1) 1
Online Resources - Pharmacy (1) 1
Regis College - Stacks (1) 1
Robarts - Storage (1) 1
Royal Ontario Museum - May be requested (1) 1
Scarborough Hospital - Withdrawn (1) 1
St Josephs Health Centre - Reference (1) 1
St Josephs Health Centre - Stacks (1) 1
St. Augustine's Seminary - Stacks (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Reference (1) 1
Thomas Fisher Rare Book - May be requested at Fisher (1) 1
Trillium Health Centre - Reserve desk (1) 1
Trillium Health Centre - Stacks (1) 1
Trinity College (John W Graham) - Storage (1) 1
UTL at Downsview - Finch Stacks (1) 1
UofT Schools - Stacks (1) 1
UofT at Scarborough - May be requested in 6-10 wks (1) 1
UofT at Scarborough - Withdrawn (1) 1
Victoria University E.J. Pratt - Coleridge (1) 1
Victoria University Emmanuel College - Birge Storage (1) 1
Victoria University Emmanuel College - Stacks (1) 1
Women's College Hospital - Pharmacy (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (28012) 28012
French (625) 625
German (572) 572
Japanese (367) 367
Spanish (223) 223
Russian (114) 114
Italian (70) 70
Polish (57) 57
Portuguese (32) 32
Dutch (30) 30
Danish (27) 27
Korean (25) 25
Chinese (23) 23
Romanian (21) 21
Hungarian (19) 19
Turkish (15) 15
Hebrew (13) 13
Norwegian (12) 12
Arabic (9) 9
Czech (9) 9
Finnish (7) 7
Croatian (6) 6
Swedish (4) 4
Latin (3) 3
Greek (2) 2
Bulgarian (1) 1
Icelandic (1) 1
Middle (1) 1
Old French (1) 1
Persian (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Management of toxicities of immune checkpoint inhibitors
by Spain, Lavinia and Diem, Stefan and Larkin, James
Cancer Treatment Reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Highlights • Role of immune checkpoint inhibition in the management of key malignancies. • Description of rates of immune-related adverse events and timing of... 
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | OPEN-LABEL | SINGLE-ARM | ANTI-CTLA-4 ANTIBODY | METASTATIC MELANOMA | ONCOLOGY | ADVANCED MELANOMA | LONG-TERM SAFETY | MALIGNANT MESOTHELIOMA | ENTERIC NEUROPATHY | ADVERSE EVENTS | IPILIMUMAB RETREATMENT | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane
by Macdonald, James B and Macdonald, Brooke and Golitz, Loren E and LoRusso, Patricia and Sekulic, Aleksandar
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 72, Issue 2, pp. 203 - 218
There has been a rapid emergence of numerous targeted agents in the oncology community in the last decade. This exciting paradigm shift in drug development... 
Vandetanib | Panitumumab | Multikinase inhibitors | Bevacizumab | Macular eruption | Pigment changes | Paronychia | Supportive oncodermatology | Drug eruption | Sunitinib | Lapatinib | Cetuximab | Gefitinib | Vascular endothelial growth factor | Pazopanib | Dasatinib | Photosensitivity | Imatinib | Mucositis | Morbilliform | Chemotherapy | Side effects | Stomatitis | Alopecia | Disturbed wound healing | Erlotinib | Sorafenib | KIT | Monoclonal antibodies | Dry skin | Nilotinib | Drug rash | Targeted therapy | erbB receptor | Toxic erythema | Papulopustular eruption | Hyperkeratotic handefoot skin reaction | Antiangiogenic agents | Platelet-derived growth factor receptor | Ranibizumab | Small molecule | Cutaneous adverse effects | Drug reaction | Epidermal growth factor receptor inhibitors | Mucocutaneous hemorrhage | Cancer treatment | Dermatologic toxicities | BCR-ABL | Xerosis | Canertinib | Tyrosine kinase inhibitors | Dual kinase inhibitors | Adverse sequelae | Genital rash | Anticancer | HER2 | cancer treatment | small molecule | sorafenib | morbilliform | photosensitivity | lapatinib | panitumumab | xerosis | chemotherapy | METASTATIC COLORECTAL-CANCER | mucocutaneous hemorrhage | canertinib | IMATINIB-INDUCED ERYTHRODERMA | bevacizumab | side effects | drug reaction | FOOT SKIN REACTION | sunitinib | papulopustular eruption | cetuximab | imatinib | gefitinib | drug rash | alopecia | EPIDERMAL-GROWTH-FACTOR | dry skin | disturbed wound healing | ADVANCED HEPATOCELLULAR-CARCINOMA | CHRONIC MYELOGENOUS LEUKEMIA | pigment changes | paronychia | stomatitis | dual kinase inhibitors | cutaneous adverse effects | anticancer | ranibizumab | epidermal growth factor receptor inhibitors | DERMATOLOGY | hyperkeratotic hand-foot skin reaction | tyrosine kinase inhibitors | antiangiogenic agents | dermatologic toxicities | drug eruption | multikinase inhibitors | dasatinib | nilotinib | platelet-derived growth factor receptor | adverse sequelae | supportive oncodermatology | targeted therapy | genital rash | FACTOR RECEPTOR INHIBITORS | macular eruption | toxic erythema | erlotinib | pazopanib | CHRONIC MYELOID-LEUKEMIA | EYELASH TRICHOMEGALY SECONDARY | mucositis | vandetanib | vascular endothelial growth factor | PLACEBO-CONTROLLED TRIAL | monoclonal antibodies | Drug Eruptions - etiology | Molecular Targeted Therapy - adverse effects | Humans | Drug Eruptions - therapy | Mucositis - chemically induced | Dose-Response Relationship, Drug | Dermatitis, Photoallergic - etiology | Antineoplastic Agents - adverse effects | Nail Diseases - chemically induced | Drug Eruptions - diagnosis | Fusion Proteins, bcr-abl - antagonists & inhibitors | Hair Diseases - chemically induced | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Alopecia - chemically induced | Angiogenesis Inhibitors - adverse effects | Cell Membrane - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Defective Regulatory T Cells In Patients with Severe Drug Eruptions: Timing of the Dysfunction Is Associated with the Pathological Phenotype and Outcome
by Takahashi, Ryo and Kano, Yoko and Yamazaki, Yoshimi and Kimishima, Momoko and Mizukawa, Yoshiko and Shiohara, Tetsuo
The Journal of Immunology, ISSN 0022-1767, 06/2009, Volume 182, Issue 12, pp. 8071 - 8079
Toxic epidermal necrolysis (TEN) and drug-induced hypersensitivity syndrome (DIHS) represent two ends of a spectrum of severe drug eruptions: DIHS is unique in... 
TYPE-1 DIABETES-MELLITUS | PROLIFERATION | SKIN | INDUCTION | IMMUNOLOGY | TOXIC EPIDERMAL NECROLYSIS | RECEPTORS | INDUCED HYPERSENSITIVITY SYNDROME | VERSUS-HOST-DISEASE | EXPRESSION | EFFECTOR-CELLS | Phenotype | Time Factors | Drug Eruptions - pathology | Humans | Cells, Cultured | Drug Eruptions - therapy | Receptors, Antigen, T-Cell - immunology | Treatment Outcome | Drug Eruptions - immunology | Protein Transport | T-Lymphocytes, Regulatory - immunology | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Drug eruption
by Tareen, Ali and Bygum, Anette
Ugeskrift for laeger, 04/2018, Volume 180, Issue 16
Drug eruption is defined as an adverse cutaneous eruption secondary to drug intake. The most frequent variation is a morbilliform exanthema, although the... 
Drug Eruptions - pathology | Drug Eruptions - diagnosis | Humans | Risk Factors | Drug Eruptions - therapy
Journal Article
Details down arrow
5. Full Text Acute generalized exanthematous pustulosis (AGEP): A review and update
by Szatkowski, Jesse, MD and Schwartz, Robert A., MD, MPH, DSc (Hon), FRCP (Edin)
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2015, Volume 73, Issue 5, pp. 843 - 848
Acute generalized exanthematous pustulosis is a severe cutaneous adverse reaction characterized by the rapid development of nonfollicular, sterile pustules on... 
Dermatology | pustular drug eruption | T cells | pustules | acute generalized exanthematous pustulosis | severe cutaneous adverse reactions | drug allergy | T cells | INVOLVEMENT | AMOXICILLIN | IL36RN MUTATIONS | DERMATOLOGY | SPECTRUM | T-CELLS | PSORIASIS | MANIFESTATIONS | Antifungal Agents - adverse effects | Lymphocyte Activation | Humans | Drug Eruptions - therapy | Withholding Treatment | CD8-Positive T-Lymphocytes | Acute Generalized Exanthematous Pustulosis - diagnosis | Acute Generalized Exanthematous Pustulosis - etiology | Acute Generalized Exanthematous Pustulosis - therapy | Drug Eruptions - diagnosis | Anti-Bacterial Agents - adverse effects | CD4-Positive T-Lymphocytes | Drug Eruptions - immunology | Medical colleges | Medicine, Preventive | Preventive health services
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Acneiform eruptions
by Dessinioti, Clio, MD and Antoniou, Christina, MD and Katsambas, Andreas, MD
Clinics in Dermatology, ISSN 0738-081X, 2014, Volume 32, Issue 1, pp. 24 - 34
Abstract Is it acne or is it not? When this question arises, we can presume that we have crossed the boundaries of “acneiform eruptions” of the face. Although... 
Dermatology | GRANULOMATOUS PERIORIFICIAL DERMATITIS | PERIORAL DERMATITIS | FACTOR RECEPTOR INHIBITORS | MANAGEMENT | SPLIT-FACE | CLINICAL PRESENTATION | PIMECROLIMUS CREAM 1-PERCENT | ACNE | DOUBLE-BLIND | ROSACEA | DERMATOLOGY | Drug Eruptions - etiology | Mite Infestations - complications | Mite Infestations - drug therapy | Rosacea - diagnosis | Humans | Acneiform Eruptions - diagnosis | Mite Infestations - diagnosis | Dermatitis, Perioral - pathology | Dermatitis, Perioral - drug therapy | Acneiform Eruptions - drug therapy | Acneiform Eruptions - etiology | Drug Eruptions - diagnosis | Lymphoma - complications | Adult | Rosacea - drug therapy | Face | Child
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Erlotinib-related skin toxicities: Treatment strategies in patients with metastatic non-small cell lung cancer
by Kiyohara, Yoshio, MD and Yamazaki, Naoya, MD and Kishi, Akiko, MD
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2013, Volume 69, Issue 3, pp. 463 - 472
Skin toxicities are the most common side effects associated with the epidermal growth factor receptor inhibitor erlotinib, occurring in most patients receiving... 
Dermatology | non-small cell lung cancer | skin toxicities | cutaneous side effects | epidermal growth factor receptor inhibitor | erlotinib | acneiform rash | Japanese patients | prevention | RASH | EFFICACY | PHASE-II | DERMATOLOGY | TYROSINE KINASE INHIBITOR | ACNEIFORM ERUPTIONS | PLACEBO-CONTROLLED TRIAL | Erlotinib Hydrochloride | Paronychia - chemically induced | Acneiform Eruptions - chemically induced | Drug Eruptions - etiology | Lung Neoplasms - drug therapy | Paronychia - drug therapy | Humans | Ichthyosis - drug therapy | Ichthyosis - chemically induced | Antineoplastic Agents - therapeutic use | Drug Eruptions - prevention & control | Acneiform Eruptions - drug therapy | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Pruritus - drug therapy | Quinazolines - therapeutic use | Quinazolines - adverse effects | Carcinoma, Non-Small-Cell Lung - drug therapy | Pruritus - chemically induced | Patient Education as Topic | Care and treatment | Epidermal growth factor | Toiletries industry | Erlotinib | Lung cancer, Small cell | Skin | Pruritus | Metastasis | Lung cancer, Non-small cell | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Fixed Drug Eruptions: Presentation, Diagnosis, and Management
by Flowers, Hal and Brodell, Robert and Brents, Melissa and Wyatt, Julie Porter
Southern Medical Journal, ISSN 0038-4348, 11/2014, Volume 107, Issue 11, pp. 724 - 727
ABSTRACTFixed drug eruption (FDE) is a well-defined, circular, hyperpigmenting plaque that recurs as one or a few lesions always in fixed locations upon... 
Drug reaction | Fixed drug eruption | Cutaneous reaction | Recurrent rash | SITE | MEDICINE, GENERAL & INTERNAL | fixed drug eruption | recurrent rash | INVOLVEMENT | cutaneous reaction | drug reaction | Drug Eruptions - etiology | Diagnosis, Differential | Drug Eruptions - physiopathology | Drug Eruptions - pathology | Drug Eruptions - diagnosis | Humans | Drug Eruptions - therapy | Dermis - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy
by Reyes-Habito, Claire Marie and Roh, Ellen K
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2014, Volume 71, Issue 2, pp. 217 - e11
Targeted drugs are increasingly being used for cancer management. They are designed to block specific cancer cell processes, and are often better tolerated... 
cutaneous reactions | cancer therapy | rash | target drugs | chemotherapy | drug hypersensitivity | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Education, Medical, Continuing | Molecular Targeted Therapy - adverse effects | Antineoplastic Agents - adverse effects | Humans | Drug Eruptions - therapy | Hedgehog Proteins - antagonists & inhibitors | Angiogenesis Inhibitors - adverse effects | Drug Delivery Systems - methods | Genetic Therapy - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Bullous disorders associated with anti–PD-1 and anti–PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy
by Siegel, Jacob and Totonchy, Mariam and Damsky, William and Berk-Krauss, Juliana and Castiglione, Frank and Sznol, Mario and Petrylak, Daniel P and Fischbach, Neal and Goldberg, Sarah B and Decker, Roy H and Stamatouli, Angeliki M and Hafez, Navid and Glusac, Earl J and Tomayko, Mary M and Leventhal, Jonathan S
Journal of the American Academy of Dermatology, ISSN 0190-9622, 12/2018, Volume 79, Issue 6, pp. 1081 - 1088
Bullous disorders associated with anti–programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) therapy are increasingly reported and may pose... 
medical dermatology | bullous pemphigoid | programmed cell death 1 | programmed cell death ligand 1 | immunotherapy | IMMUNE | NIVOLUMAB | PD-1 | DERMATOLOGY | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Tertiary Care Centers | Pemphigoid, Bullous - chemically induced | Humans | Lichenoid Eruptions - chemically induced | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Treatment Outcome | Adrenal Cortex Hormones - therapeutic use | Nivolumab - adverse effects | Neoplasms - drug therapy | Neoplasms - complications | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - antagonists & inhibitors | Drug Eruptions - drug therapy | Skin Diseases, Vesiculobullous - chemically induced | Female | Aged | Retrospective Studies | Skin Diseases, Vesiculobullous - drug therapy | Antimitotic agents | Medical research | Care and treatment | Cell death | Immunotherapy | Medicine, Experimental | Medical records | Development and progression | Antineoplastic agents | Health aspects | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Understanding, recognizing, and managing toxicities of targeted anticancer therapies
by Dy, Grace K and Adjei, Alex A
CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 07/2013, Volume 63, Issue 4, pp. 249 - 279
Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for... 
toxicity | kinase inhibitors | therapeutic index | targeted agents | mechanism‐based toxicity | immunotherapeutic agents | off‐target toxicity | mechanism-based toxicity | off-target toxicity | MEK INHIBITOR TRAMETINIB | PULMONARY ARTERIAL-HYPERTENSION | I DOSE-ESCALATION | CHRONIC MYELOID-LEUKEMIA | GROWTH-FACTOR RECEPTOR | ONCOLOGY | PLACEBO-CONTROLLED TRIAL | III CLINICAL-TRIAL | SQUAMOUS-CELL CARCINOMAS | TIVANTINIB ARQ 197 | SIGNAL-REGULATED KINASE | Mood Disorders - chemically induced | Drug Eruptions - etiology | Peripheral Nervous System Diseases - chemically induced | Bone Marrow Diseases - chemically induced | Cachexia - chemically induced | Endocrine System Diseases - chemically induced | Pleural Effusion - chemically induced | Humans | Drug Eruptions - therapy | Immune System Diseases - chemically induced | Lung Diseases, Interstitial - chemically induced | Thrombocytopenia - chemically induced | Diarrhea - chemically induced | Neoplasms - drug therapy | Antineoplastic Agents - adverse effects | Exanthema - chemically induced | Hyperbilirubinemia - chemically induced | Venous Thromboembolism - chemically induced | Vision Disorders - chemically induced | Hemorrhage - chemically induced | Heart Diseases - chemically induced | Hyperlipidemias - chemically induced | Magnesium - blood | Antimitotic agents | Drugs | Prevention | Complications and side effects | Drug targeting | Antineoplastic agents | Health aspects | Risk factors | Proteins | Side effects | Genomics | Cytotoxicity | Molecular biology | Cancer therapies | Cells | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights